AG真人官方

STOCK TITAN

Imunon Inc SEC Filings

IMNN NASDAQ

Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Non-viral DNA immunotherapies sound promising鈥攜et Immunon鈥檚 disclosures are packed with molecular biology, trial protocols, and shifting cash-runway projections. If you have ever searched "What does Immunon report in their SEC filings?" or scrambled to locate Immunon insider trading Form 4 transactions before the market opens, you know how challenging this data hunt can be.

Stock Titan solves the problem. Our AI parses every document鈥攚hether it is the Immunon annual report 10-K simplified or an Immunon quarterly earnings report 10-Q filing鈥攁nd serves concise explanations you can act on. Stop scrolling through clinical tables: our platform flags R&D spend shifts, highlights trial milestones buried in an Immunon 8-K material events explained, and even sends alerts for Immunon Form 4 insider transactions real-time. Key features include:

  • AI-powered summaries that turn dense science into plain English鈥攑erfect for understanding Immunon SEC documents with AI
  • Instant access to Immunon executive stock transactions Form 4 and ownership changes
  • Side-by-side financial trend visualizations for rapid Immunon earnings report filing analysis
  • Full proxy coverage, so Immunon proxy statement executive compensation details are never missed
  • AG真人官方-time feeds direct from EDGAR鈥攗pdates arrive seconds after filing

Whether you鈥檙e modeling cash burn or gauging sentiment shifts after a Phase II readout, our tools keep you ahead. From "Immunon SEC filings explained simply" to granular drill-downs of trial expenditures, Stock Titan delivers the clarity professionals require.

Rhea-AI Summary

Forrester Research (FORR) Q2 2025 10-Q highlights:

Total revenue fell 8.3 % YoY to $111.7 m as Research 鈭�6.9 %, Consulting 鈭�5.3 % and Events 鈭�23.3 %. Cost discipline narrowed operating expenses 5.3 %, yet operating income dropped 38 % to $7.0 m; diluted EPS slipped to $0.20 (vs $0.33).

Six-month view: revenue down 9.2 % to $201.5 m. A Q1 goodwill impairment of $83.9 m drove a net loss of $-83.4 m (-$4.39 per share) and cut equity to $159.5 m (-30 % YTD). Operating cash flow swung positive to $23.1 m vs $-2.3 m, boosting cash & equivalents to $67.8 m; liquidity is further supported by $67.2 m in marketable investments and $114 m of unused revolver capacity.

Balance sheet shifts: goodwill reduced to $147.4 m; AOCI improved with $7.4 m FX gains. Deferred revenue rose 6.3 % to $154.5 m, signalling backlog durability. Net debt remains modest at $-32.8 m (cash > debt).

Cost actions & risks: a January workforce reduction (鈮�6 %) added $2.0 m restructuring cost in H1; remaining accrual $1.3 m. Cambridge HQ lease amended, extending term to 2039 and increasing ROU assets $9.8 m. Management warns further goodwill tests could be required if macro softness persists.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Filing
Rhea-AI Summary

Form 8-K (Item 2.02) 鈥� Imunon, Inc. (NASDAQ: IMNN) is furnishing, not filing, its Q2-25 financial results press release and related conference-call details.

  • The company issued a press release on 5 Aug 2025 covering results for the quarter ended 30 Jun 2025; the full text is attached as Exhibit 99.1.
  • A live webcast and teleconference to review the quarter and provide a business update will be held the same day (5 Aug 2025) and can be accessed at www.imunon.com.
  • Under SEC rules, the furnished information is exempt from liability under Exchange Act 搂18 and will not be incorporated by reference into other SEC filings unless specifically stated.
  • No quantitative financial figures, guidance, or strategic actions are included in this 8-K; investors must refer to Exhibit 99.1 for actual performance metrics.

Other than the routine disclosure of results timing and webcast logistics, the filing contains no material new information or corporate actions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Filing
Rhea-AI Summary

Imunon, Inc. filed a Form 8-K on 28 Jul 2025 reporting that its Board of Directors has approved a 15% stock dividend, equal to 0.15 additional shares for every outstanding share and each common-stock equivalent with dividend rights. The Board set 7 Aug 2025 as the record date and 21 Aug 2025 as the payment date. Exhibit 99.1 contains the related press release; no other material events, financial results, or transactions were disclosed. The information in the exhibit is furnished, not filed, under the Exchange Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
current report
Filing
Rhea-AI Summary

Imunon, Inc. filed a Form 8-K reporting that it amended its Certificate of Incorporation to implement a 1-for-15 reverse stock split of its common stock. The Certificate of Amendment was filed on 21 Jul 2025 and the split becomes effective 25 Jul 2025 at 12:01 a.m. ET.

At the effective time, every fifteen pre-split shares will be combined into one post-split share, reducing the number of outstanding shares from approximately 31.8 million to 2.1 million. Authorized share counts, par value and voting rights remain unchanged. Post-split shares will continue trading on Nasdaq under ticker IMNN with a new CUSIP 15117N701.

No fractional shares will be issued; stockholders otherwise entitled to fractions will receive one whole post-split share. Equiniti Trust Company is the exchange agent. Book-entry holders need not act; broker-held positions adjust automatically. The share reduction is proportionally reflected in all active S-1, S-3 and S-8 registration statements pursuant to Rule 416(b).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.8%
Tags
current report
-
Filing
Rhea-AI Summary

Imunon, Inc. (IMNN) filed an 8-K reporting the expansion of its at-the-market (鈥淎TM鈥�) equity program with H.C. Wainwright. A new prospectus supplement registers an additional $4.5 million in common shares, taking total capacity to $10 million. The company has already sold $1.82 million under the agreement, leaving roughly $8.18 million available for future issuance at prevailing market prices. Thompson Hine LLP鈥檚 legality opinion on the shares is filed as Exhibit 5.1. No financial results, guidance, or operational updates were included; the filing is limited to disclosure of the enlarged equity facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Fusion Fuel Green PLC (HTOO) has furnished a Form 6-K disclosing that, on 22 July 2025, it released a press statement announcing the execution of a non-binding Term Sheet (dated 17 June 2025) between its subsidiary Bright Hydrogen Solutions Ltd. and an unidentified partner. The filing provides no financial terms, project scope, timeline, or capital commitments. Completion of any transaction will depend on completion of due diligence, negotiation of definitive agreements, partner financing, and receipt of regulatory approvals. The document is largely comprised of standard forward-looking-statement disclaimers and attaches the press release as Exhibit 99.1; no other operational or financial updates are included.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
Filing
Rhea-AI Summary

Coinbase Global, Inc. (COIN) 鈥� Form 144 filing dated 07/14/2025

The Brian Armstrong Living Trust, a vehicle for Coinbase鈥檚 co-founder and Chief Executive Officer, has filed a Form 144 indicating an intent to sell 165,443 Class A common shares. Based on the stated aggregate market value of $65.2 million, the implied reference price is roughly $394 per share. The planned sale represents 0.08 % of Coinbase鈥檚 211.4 million shares outstanding and will be executed through Goldman Sachs & Co. LLC on the NASDAQ.

The filing also discloses extensive prior sales by the same trust during the past three months:

  • Approx. 846,000 shares sold between 04/14/2025 and 07/11/2025.
  • Two block trades stand out 鈥� 336,265 shares on 06/25/2025 for $121.9 million and 113,735 shares on 06/26/2025 for $41.3 million.
  • Cumulative disclosed gross proceeds over the period exceed $215 million.

No mention is made of any material non-public information, and the signatory affirms compliance with Rule 10b5-1. While the percentage of total shares is modest, the continuing pattern of sizeable insider sales by Coinbase鈥檚 CEO may influence investor sentiment and raise questions about management鈥檚 outlook or personal diversification.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Filing
Rhea-AI Summary

Pearl Diver Credit Company Inc. (NYSE: PDCC) filed a Form 8-K to disclose a single data point under Item 8.01 鈥� Other Events. Management has calculated the company鈥檚 unaudited net asset value (NAV) per common share at $18.19 as of June 30, 2025. No additional financial statements, earnings details, or transaction announcements were included. The filing is therefore informational, providing shareholders with an updated valuation reference ahead of future periodic reports.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Imunon (IMNN)?

The current stock price of Imunon (IMNN) is $8.76 as of August 5, 2025.

What is the market cap of Imunon (IMNN)?

The market cap of Imunon (IMNN) is approximately 18.0M.

What is the primary focus of Immunon Inc?

Immunon Inc is focused on developing non-viral DNA immunotherapies that harness the body鈥檚 immune system to combat diseases such as ovarian cancer and support vaccine development.

How does Immunon Inc differentiate itself from other biopharmaceutical companies?

The company differentiates itself through its innovative non-viral DNA technology, which is designed to safely induce durable immune responses, setting it apart from traditional viral-based therapies.

What are the core clinical programs of Immunon Inc?

Immunon Inc has a diverse clinical pipeline, including IMNN-001, a DNA-based immunotherapy for ovarian cancer, and IMNN-101, a first-in-human study for a COVID-19 booster vaccine.

What is the significance of non-viral DNA technology in their treatments?

This technology offers a controlled mechanism for stimulating immune responses without the risks associated with viral vectors, allowing for potentially safer and more targeted therapies.

How does Immunon Inc approach research and development?

The company employs a bench-to-bedside approach, rigorously translating laboratory discoveries into clinical applications through well-structured clinical studies and robust research protocols.

Which therapeutic areas does Immunon Inc target?

Immunon Inc targets oncology, particularly ovarian cancer, and has expanded its focus to include infectious diseases, as shown by its clinical investigation into a COVID-19 booster vaccine.

What challenges does Immunon Inc face in its market?

Like many clinical-stage biotech firms, Immunon Inc faces challenges including regulatory hurdles, the need for rigorous clinical validation, and competition from both established and emerging biotechnology companies.

How can investors learn more about Immunon Inc's advancements?

Investors can study the company鈥檚 detailed clinical reports and technological insights provided in public filings and industry analyses to understand its research progress and underlying scientific strategies.
Imunon Inc

NASDAQ:IMNN

IMNN Rankings

IMNN Stock Data

18.04M
2.03M
4.31%
1.15%
1.47%
Biotechnology
Pharmaceutical Preparations
United States
LAWRENCEVILLE